Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 11/20 | 1.00 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 1.00 |
| ▸ | DHFR known ✓ | P00374 | 4/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 7/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 6/20 | 1.00 |
| ▸ | FOLR2 | P14207 | 3/20 | 1.00 |
| ▸ | ATIC | P31939 | 2/20 | 1.00 |
| ▸ | SHMT1 | P34896 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL5959741 | 1.00 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL7144918 | 1.00 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL14321276 | 0.99 | GART (0.98) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL1933381 | 0.99 | GART (0.98) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL24846092 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967346 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL15078815 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967345 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967367 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL29710616 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-12607639-B2 | Diagnostic blood test for sarcoidosis | MOLLER DAVID R (US) | 2026-04-21 | — | — | US | claimed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4642537-A2 | A GLUCOSAMINE COMPOUND AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUITABLE FOR USE IN THE TREATMENT OF BREAST CANCER AND RELIEF OF SYMPTOMS RESULTING FROM SUCH DISEASES | Mugla Sitki Kocman Universitesi Strateji Gelistirme Daire Baskanligi (TR) | 2025-11-05 | — | — | EP | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250195686-A1 | D GLUTAMATE POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-06-19 | — | — | US | claimed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | claimed |
| EP-4554570-A1 | TREATMENT OF CELL PROLIFERATION-ASSOCIATED CONDITIONS USING A COMBINATION OF A CLB-B INHIBITOR AND AN ADDITIONAL THERAPEUTIC AGENT | Hotspot Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| EP-3749313-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | claimed |
| US-20200360389-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2020-11-19 | — | — | US | claimed |
| WO-2019157146-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | claimed |
| EP-2997031-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY AMORPHOUS PEMETREXED DISODIUM AND CRYSTALLINE FORMS OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3- D]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID | Instytut Farmaceutyczny (PL) | 2016-03-23 | — | — | EP | claimed |
| WO-2014185797-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY AMORPHOUS PEMETREXED DISODIUM AND CRYSTALLINE FORMS OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3- D] PYRIMIDIN-5-YL)ETHYL] BENZOYL]-L-GLUTAMIC ACID | INSTYTUT FARMACEUTYCZNY (PL) | 2014-11-20 | — | — | WO | claimed |
| EP-2797920-A1 | ONE POT PROCESS FOR PREPARING PEMETREXED DISODIUM | Kocak Farma Ilac Ve Kimya San. A.S (TR) | 2014-11-05 | — | — | EP | claimed |
| WO-2013100872-A1 | ONE POT PROCESS FOR PREPARING PEMETREXED DISODIUM | KOÇAK FARMA ILAÇ VE KIMYA SANAYI A. Ş. (TR) | 2013-07-04 | — | — | WO | claimed |
| US-20040247600-A1 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. | 2004-12-09 | — | — | US | claimed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | claimed |
| EP-1259513-B1 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | LILLY CO ELI (US) | 2003-09-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | KLF10, SLC11A2, SLC7A11 | GART 2805/4885TYMS 2331/4885DHFR 4193/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | GART 573/4885TYMS 62/4885DHFR 14/4885 |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | GART 57/4885TYMS 70/4885DHFR 113/4885 |
| US-12607639-B2 | Diagnostic blood test for sarcoidosis | IFNG, HLA-A, CAT | GART 4167/4885TYMS 1316/4885DHFR 2810/4885 |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | GART 577/4885TYMS 68/4885DHFR 6/4885 |
| US-20200360389-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | GART 573/4885TYMS 62/4885DHFR 14/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | GART 577/4885TYMS 68/4885DHFR 6/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | GART 968/4885TYMS 16/4885DHFR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.